Upload
Featured Recent Articles Topics Login Upload

Search Results for 'rbv sof'

rbv sof published presentations and documents on DocSlides.

SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
SOF/VEL
SOF/VEL
by trish-goza
400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...
SOF/VEL 400/100 mg qd N = 75
SOF/VEL 400/100 mg qd N = 75
by danika-pritchard
W24. SOF/VEL. >. 18 years. Chronic HCV infect...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
SIRIUS
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
Safety and Efficacy of Daclatasvir
Safety and Efficacy of Daclatasvir
by tabitha
. Plus . Sofosbuvir. With or Without Ribavirin . ...
Daclatasvir in Combination With Sofosbuvir
Daclatasvir in Combination With Sofosbuvir
by mitsue-stanley
With Or Without Ribavirin Is Safe and Efficacious...
Daclatasvir in Combination With Sofosbuvir
Daclatasvir in Combination With Sofosbuvir
by mitsue-stanley
With Or Without Ribavirin Is Safe and Efficacious...
Sofosbuvir, Ribavirin, GS
Sofosbuvir, Ribavirin, GS
by min-jolicoeur
-. 0938 in GT 1-4. QUANTUM. Phase . 2b. Treatment...
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection:
by kittie-lecroy
Interim Analysis of a French Multicenter Compassi...
EASL 2019 HCV Conference Update
EASL 2019 HCV Conference Update
by sophia
April 10. –14. , 2019. Vienna, Austria. Disclaim...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
HIV and HCV Update for the Pharmacist – June 2014
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
Out With the Old and In With the New, Again?
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Use of HCV DAAs with HIV Regimens
Use of HCV DAAs with HIV Regimens
by robaut
Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....
HIV Pipeline Cabotegravir-LA
HIV Pipeline Cabotegravir-LA
by liane-varnes
(GSK-744; CAB). For . PrEP. INI. ViiV. Topical mi...
Community Pharmacy Considerations for HIV
Community Pharmacy Considerations for HIV
by tawny-fly
& HCV . Therapy. Larry Pineda, . PharmD. , . ...
HIV Pipeline Doravirine 2
HIV Pipeline Doravirine 2
by giovanna-bartolotta
(MK-1439; DOR). . NNRTI. Merck. Filed with USFDA...
ALLY-1
ALLY-1
by stefany-barnette
Design. Objective. SVR. 12. (HCV RNA < 25 IU/...
Ledipasvir-Sofosbuvir (
Ledipasvir-Sofosbuvir (
by lindy-dunigan
Harvoni. ). Prepared by: . David H. Spach, MD and...
Are Pan-Genotypic Therapies Ready for Prime Time?
Are Pan-Genotypic Therapies Ready for Prime Time?
by lois-ondreau
3. Rd. International . HIV/Hepatitis . Coinfecti...
Sofosbuvir
Sofosbuvir
by conchita-marotz
ELECTRON (Overview): 6 parts, 22 arms. Phase . 2....
CURRY
CURRY
by faustina-dinatale
Design. Open-label. CURRY . Study. : SOF + RBV fo...